Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer
August 24th 2023Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.
Read More